InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod

InDex Pharmaceuticals Holding AB announced positive results from a pharmacokinetic study with cobitolimod in patients with moderate to severe ulcerative colitis.